DOCSLIB.ORG

Clinical Chemistry Issue No

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Clinical Chemistry Issue No Primary Sample Manual – Clinical Chemistry Issue No. 4.05 Effective Date: 15/07/20 Page 1 of 98 EUROFINS BIOMNIS Written / Revised By: Date: Barry O’Dea, Medical Scientist Reviewed By: Date: Dr. Mike Louw, Medical Director Authorised By: Date: Jean-Sébastien Charles, QA Manager Effective Date: 15/07/20 Supersedes: 4.04 File Type: Master Assigned to: Quality Department Electronic copies are available to all staff on Q-Pulse and on the Eurofins Biomnis website. Additional copies of this SOP must not be made without prior approval and documentation. Refer to SOP G94. Issue No. Revision Details Effective Date 1.01 Original 18/04/11 1.02 Added: Theophyline, C3, C4, Tacrolimus, Digoxin, Hepatitis C 31/08/12 Ag, Troponine I, IGF-1 1.03 Added consultant reference 25/10/12 1.04 Full review: Removed immunology and infectious serology 06/05/15 tests. Included reference ranges and source for IgE. 1.05 Updated SOP numbers and accreditation status for several 30/09/15 tests. 1.06 Updated phosphate reference range and PLAC-2 TAT. 01/02/16 Updated gentamicin therapeutic range comment to reflect new Abbott IFU 1E11-20 May 2014 306414/R06. 1.07 Added new test: lipase. Corrected ref ranges TSH, Lp(a) 26/05/16 1.08 Add new in-house tests: lipase, A1AT, caeruloplasmin, 04/01/17 fructosamine, urine free cortisol, urine total protein. Corrected reference ranges for TSH and Lp(a). Updated accreditation status of several tests. 1.09 Addition of anti-thyroglobulin and anti-TPO antibodies. 18/01/17 2.01 Updating of sample requirements for glucose. Update of 04/04/17 reference range for urine sodium in spot sample. Update of link to France test guide. Methods updated for Ferritin, Gentamicin, Glucose, Homocysteine, Vancomycin. 3.01 Remove EDTA plasma as suitable sample for SHBG following 24/05/17 Abbott Field Safety notice dated 18/04/2017. Eurofins Biomnis rebranding. 3.02 Addition of plasma as suitable sample type for iron. Addition of 09/03/18 ACE test and accreditation of caeruloplasmin. 3.03 Updated FT3 reference range. Updated Bile acid method and 29/06/18 sample types. PRODUCTION OF UNAUTHORISED COPIES OF THIS SOP IS FORBIDDEN. AUTHORISED COPIES ARE STAMPED IN GREEN – OFFICIAL COPY Primary Sample Manual – Clinical Chemistry Issue No. 4.05 Effective Date: 15/07/20 Page 2 of 98 EUROFINS BIOMNIS Issue No. Revision Details Effective Date 3.04 Updated transferrin and PSA sample stability. Removed 18/04/19 Troponin I. Updated hyperlink. Added LDH and CK. Updated B12 reference ranges. 3.05 Updated ACE to Glenbio assay. New reference ranges 24/05/19 Updated maximum storage time for C3, IGA, IGG, IGM. EDTA not anymore acceptable for those tests. Updated PSA stability. 3.06 Marked CK as unaccredited 29/05/19 3.07 Updated PSA reference ranges 29/05/19 3.08 Updated C3, C4 and caeruloplasmin sample types. Removed 22/07/19 Red Cell Folate. 3.09 Updated accreditation status for A1AT, theophylline, SPE, 27/09/19 immunofixation. Added back TSH. 4.01 Updated urinary calcium details. SPE method updated to 16/03/20 Capillarys 3 Octa. 4.02 Added lithium. 20/04/20 4.03 Updated with urine chemistry reference ranges 06/06/20 Replace BNP with NTproBNP 4.04 Updated FT3 reference range 10/06/20 4.05 Update anti-TPO units from kIU/L to IU/mL as per IFU 15/07/20 PRODUCTION OF UNAUTHORISED COPIES OF THIS SOP IS FORBIDDEN. AUTHORISED COPIES ARE STAMPED IN GREEN – OFFICIAL COPY Primary Sample Manual – Clinical Chemistry Issue No. 4.05 Effective Date: 15/07/20 Page 3 of 98 EUROFINS BIOMNIS INTRODUCTION This is a list of the biochemistry, endocrinology, and therapeutic drug monitoring tests performed at Eurofins Biomnis’ Dublin Laboratory. For a searchable list of tests performed by Eurofins Biomnis in France, in our laboratories in Lyon and Paris, click here. Please note that these lists were complete at the time of publishing. Eurofins Biomnis is continuously updating its menu of tests, and some tests may be available even though they are not listed in this document or at the above link. If you cannot find details of a test you require, please contact our Client Services department on Free Phone 1800-252-966, or e- mail [email protected]. For sample collection, please contact our Logistics department on Free Phone 1800-252-967, or e-mail [email protected]. PRODUCTION OF UNAUTHORISED COPIES OF THIS SOP IS FORBIDDEN. AUTHORISED COPIES ARE STAMPED IN GREEN – OFFICIAL COPY Primary Sample Manual – Clinical Chemistry Issue No. 4.05 Effective Date: 15/07/20 Page 4 of 98 EUROFINS BIOMNIS LAYOUT OF TEST INFORMATION TEST INFORMATION TEMPLATE Brief information on clinical background, indications for test and interpretation of test results. Preparation of Patient: any special preparation required, such as fasting. Precautions: any special circumstances, conditions etc. to be aware of. Accredited Whether or not the test is accredited by INAB to ISO 15189 Method Test method Sample Type of tube required, transport temperature and other information. Requirements Avoid gel separation tubes for therapeutic drug assays. Some gels (depending on manufacturer) cause adsorption of the drug to the gel. Turnaround The maximum turnaround time in working days from receipt of the Time sample in the laboratory’s pre-analytics department to final authorisation of results. Stability Sample stability under various conditions. RT = room temperature i.e.: 16 – 25 °C. Please see SAMPLE STABILITY notes below. Stability data indicated by a superscript numeral 1 are taken from the publication referenced below1. Units - Units and reference range(s) for the test. Reference Source of the reference ranges: Ranges and 1. Test manufacturer’s instructions for use (IFU). Source 2. National and international guidelines. 3. Ranges established in-house. PRODUCTION OF UNAUTHORISED COPIES OF THIS SOP IS FORBIDDEN. AUTHORISED COPIES ARE STAMPED IN GREEN – OFFICIAL COPY Primary Sample Manual – Clinical Chemistry Issue No. 4.05 Effective Date: 15/07/20 Page 5 of 98 EUROFINS BIOMNIS NOTES ON SAMPLE STABILITY The majority of incorrect laboratory test results are due to improper sample collection and transport. For details regarding correct phlebotomy technique and our patient identification requirements, please click here. In order for you to arrange and properly time phlebotomy and sample collection, we have indicated, for each test, its stability after collection. Stability is indicated for whole blood at various temperatures, and for plasma or serum separated from cells, also at various temperatures. Note: RT = room temperature, i.e. 16 – 25 °C. Stability data are taken from the manufacturers’ instructions for use (IFUs), and from the World Health Organisation publication indicated below1. Sample stability data is not available for all tests under all conditions, either in the manufacturers’ IFUs or the published literature. If no information is available, in general, unless otherwise specified (such as when the required sample is whole blood), serum should be centrifuged and separated from cells after completion of clotting (20 – 30 minutes), and transported to the laboratory at 2 – 8 °C. Plasma may be centrifuged and separated from cells immediately after sampling and gently mixing the sample by inverting the tube 10 times. It should then be transported to the laboratory at 2 – 8 °C. Whole blood should be transported at 2 – 8 °C and reach the laboratory as soon as possible. However, please check each test for specific stability information. If in doubt, please contact our Client Services department on Free Phone 1800-252-966, or e- mail [email protected]. Reference: 1. World Health Organisation: Use of anticoagulants in diagnostic laboratory investigations. WHO/DIL/LAB99.1 Rev.2, 2002. 2. Clinical Biochemistry 45 (2012) 464–469. PRODUCTION OF UNAUTHORISED COPIES OF THIS SOP IS FORBIDDEN. AUTHORISED COPIES ARE STAMPED IN GREEN – OFFICIAL COPY Primary Sample Manual – Clinical Chemistry Issue No. 4.05 Effective Date: 15/07/20 Page 6 of 98 EUROFINS BIOMNIS REASONS FOR REJECTION OF SAMPLES/NON-REPORTING OF TESTS 1. Samples received beyond the stability limits and/or not at the correct temperature indicated below for each test. 2. Samples received in the incorrect tube/with the incorrect anticoagulant or lack of the correct anticoagulant. 3. Samples received without the necessary patient identifiers. For more details, see here. 4. Samples which fail specific criteria for certain tests. See individual tests for details. 5. All samples have 3 tests run on them called “serum indices”. These measure the extent of haemolysis, lipaemia and icterus in the sample. Each test has a specific level of each of these indices above which the test result is not valid. If any index is too high for a given test, that test is not reported. A comment such as “result invalid; sample haemolysed” is printed on the report instead. Clinical Chemistry Consultant: Dr. Mike Louw Telephone: 00-353-1-295-8545 PRODUCTION OF UNAUTHORISED COPIES OF THIS SOP IS FORBIDDEN. AUTHORISED COPIES ARE STAMPED IN GREEN – OFFICIAL COPY Primary Sample Manual – Clinical Chemistry Issue No. 4.05 Effective Date: 15/07/20 Page 7 of 98 EUROFINS BIOMNIS CONTENTS TEST INFORMATION TEMPLATE ............................................................................. 4 ALANINE AMINOTRANSFERASE (ALT) ................................................................... 10 ALBUMIN ............................................................................................................. 11 ALKALINE PHOSPHATASE (ALP) ...........................................................................
Load more

Recommended publications
  • Clinical Study Is Nonmicronized Diosmin 600Mg As Effective As
    Hindawi International Journal of Vascular Medicine Volume 2020, Article ID 4237204, 9 pages https://doi.org/10.1155/2020/4237204 Clinical Study Is Nonmicronized Diosmin 600mg as Effective as Micronized Diosmin 900mg plus Hesperidin 100mg on Chronic Venous Disease Symptoms? Results of a Noninferiority Study Marcio Steinbruch,1 Carlos Nunes,2 Romualdo Gama,3 Renato Kaufman,4 Gustavo Gama,5 Mendel Suchmacher Neto,6 Rafael Nigri,7 Natasha Cytrynbaum,8 Lisa Brauer Oliveira,9 Isabelle Bertaina,10 François Verrière,10 and Mauro Geller 3,6,9 1Hospital Albert Einstein (São Paulo-Brasil), R. Mauricio F Klabin 357/17, Vila Mariana, SP, Brazil 04120-020 2Instituto de Pós-Graduação Médica Carlos Chagas-Fundação Educacional Serra dos Órgãos-UNIFESO (Rio de Janeiro/Teresópolis- Brasil), Av. Alberto Torres 111, Teresópolis, RJ, Brazil 25964-004 3Fundação Educacional Serra dos Órgãos-UNIFESO (Teresópolis-Brasil), Av. Alberto Torres 111, Teresópolis, RJ, Brazil 25964-004 4Faculdade de Ciências Médicas, Universidade Estadual do Rio de Janeiro (UERJ) (Rio de Janeiro-Brazil), Av. N. Sra. De Copacapana, 664/206, Rio de Janeiro, RJ, Brazil 22050-903 5Fundação Educacional Serra dos Órgãos-UNIFESO (Teresópolis-Brasil), Rua Prefeito Sebastião Teixeira 400/504-1, Rio de Janeiro, RJ, Brazil 25953-200 6Instituto de Pós-Graduação Médica Carlos Chagas (Rio de Janeiro-Brazil), R. General Canabarro 68/902, Rio de Janeiro, RJ, Brazil 20271-200 7Department of Medicine, Rutgers New Jersey Medical School-USA, 185 S Orange Ave., Newark, NJ 07103, USA 8Hospital Universitário Pedro Ernesto, Universidade Estadual do Rio de Janeiro (UERJ) (Rio de Janeiro-Brazil), R. Hilário de Gouveia, 87/801, Rio de Janeiro, RJ, Brazil 22040-020 9Universidade Federal do Rio de Janeiro (UFRJ) (Rio de Janeiro-Brazil), Av.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Calcium Dobesilate Versus Micronised Purified Flavonoid Fraction of Diosmin in the Treatment of Chronic Venous Disease: a Randomized Prospective Study
    Acta Medica Mediterranea, 2018, 34: 657 CALCIUM DOBESILATE VERSUS MICRONISED PURIFIED FLAVONOID FRACTION OF DIOSMIN IN THE TREATMENT OF CHRONIC VENOUS DISEASE: A RANDOMIZED PROSPECTIVE STUDY EMINE SEYMA DENLI YALVAC1, MURAT DEMIROĞLU2, SIDIKA GURSEL1, EBUZER AYDIN1 ¹Medeniyet University Faculty of Medicine, Department of Cardiovascular Surgery, Istanbul, Turkey - 2Medeniyet University Faculty of Medicine, Department of Department of Orthopedics and Traumatology, Istanbul, Turkey ABSTRACT Introduction: Chronic venous disease (CVD) of the lower extremities has a substantial effect on quality of life. The clinical, etiology, anatomy, pathophysiology classification (CEAP) is a frequently used classification for CVD. Patients with varicose veins are classified as CEAP class C2. Veno-active drugs (VAD) such as Calcium Dobesilate or Micronised Purified Flavonoid Fraction of Diosmin (MPFF) reduce the symptoms of pain associated with CVD. However, although the effectiveness of VAD is well established, it is controversial. The aims of the this study were to compare the efficacy of two VAD (Calcium dobesilate and MPFF in the treat- ment of CVD in view of the intended visual analogue scale (VAS) and duplex scanning (DS) changes such as measuring great saphe- nous vein (GSV) diameter. Materials and methods: A total of 24 patients who had no prior VAD treatment with CEAP class C2, with no family history of CVD were treated; 12 received calcium dobesilate and 12 received MPFF for 60 days. Comorbidities such as hypertension (HT) and diabetes mellitus (DM) were examined. Before and after treatment period, the patients were investigated with DS for diameter of GSV and pain complaint according to VAS were recorded. Results: There were no difference in treatment groups in terms of age, gender, or the comorbidities.
    [Show full text]
  • Appendices Feb 2010 Inclusion of Cobalt and 2019 Fei Prohibited
    APPENDIX 2 CLASSIFICATION OF PROHIBITED SUBSTANCES 1. This classification describes the types of Prohibited Substances and places same in specific categories. The list shall be published on the Club’s Notice Board. CLASS I Drugs that have the greatest pharmacological potential to affect the racing performance of a horse and which have no accepted medical use in a racehorse. These include substances which are potent stimulants of the Central Nervous System (CNS). Examples of drugs in this Class include, but are not limited to: Amphetamines, fentanyl, etorphine, cocaine, morphine, meperidine, opiates, opium derivatives, synthetic opiods, psychoactive drugs. CLASS II Drugs that have a high pharmacological potential for affecting the racing performance of a horse. These include: (i) substances which are pharmacologically active in altering the cons (ii) substances which are not generally accepted as therapeutic agents in the racing horse; and (iii) substances, some of which may have legitimate use in equine medicine but should not be found in the racing horse, such as injectable local anaesthetics. 1 Groups of drugs in this Class include, but are not limited to: (a) Opiate partial agonists, or agonistsantagonists; (b) Non-opiate psychotropic drugs, which may have stimulant, depressant, analgesic or neuroleptic effects; (c) Miscellaneous drugs which might have a stimulant effect on the CNS; (d) Drugs with prominent CNS depressant action; (e) Antidepressant and antipsychotic drugs, with or without prominent CNS stimulatory or depressant effects; (f) Muscle blocking drugs which have direct neuromuscular blocking action; (g) Local anaesthetics which have a reasonable potential for use as nerve blocking agents (except procaine); and (h) Snake venom and other biologic substances which may be used as nerve blocking agents.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Rabe E, Ballarini S, Lehr L; Doxium EDX09/01 Study Group
    1: Rabe E, Ballarini S, Lehr L; Doxium EDX09/01 Study Group. A randomized, double-blind, placebo-controlled, clinical study on the efficacy and safety of calcium dobesilate in the treatment of chronic venous insufficiency. Phlebology. 2015 May 18. pii: 0268355515586097. [Epub ahead of print] PubMed PMID: 25991692. 2: Rabe E, Agus GB, Roztocil K. Analysis of the effects of micronised purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomised trial. Int Angiol. 2015 May 14. [Epub ahead of print] PubMed PMID: 25972136. 3: Mosti G, De Maeseneer M, Cavezzi A, Parsi K, Morrison N, Nelzen O, Rabe E, Partsch H, Caggiati A, Simka M, Obermayer A, Malouf M, Flour M, Maleti O, Perrin M, Reina L, Kalodiki E, Mannello F, Rerkasem K, Cornu-Thenard A, Chi YW, Soloviy M, Bottini O, Mendyk N, Tessari L, Varghese R, Etcheverry R, Pannier F, Lugli M, Carvallo Lantz AJ, Zamboni P, Zuolo M, Godoy MF, Godoy JM, Link DP, Junger M, Scuderi A. Society for Vascular Surgery and American Venous Forum Guidelines on the management of venous leg ulcers: the point of view of the International Union of Phlebology. Int Angiol. 2015 Jun;34(3):202-18. Epub 2015 Apr 21. PubMed PMID: 25896614. 4: Pannier F, Rabe E. Progression in venous pathology. Phlebology. 2015 Mar;30(1 Suppl):95-7. doi: 10.1177/0268355514568847. Review. PubMed PMID: 25729075. 5: Rabe E, Pannier F. Embolization is not essential in the treatment of leg varices due to pelvic venous insufficiency.
    [Show full text]
  • Hemorrhoids (1 of 8)
    Hemorrhoids (1 of 8) 1 Patient presents w/ symptoms of hemorrhoids 2 DIAGNOSIS No ALTERNATIVE Hemorrhoids confi rmed & other DIAGNOSIS causes of rectal bleeding excluded? Yes Internal or external External TREATMENT hemorrhoids? hemorrhoids See page 3 Internal hemorrhoids 3 GRADE HEMORRHOIDS A Dietary modifi cation & supportive measures B Pharmacological therapy Grade I - II Grade III Grade IV Yes Response to C Ablative offi ce procedures therapy? D Surgical hemorrhoidectomy CONTINUE No TREATMENT C Ablative offi ce procedures Yes Response to No D Surgical hemorrhoidectomy ©therapy? MIMS B1 © MIMS 2019 Hemorrhoids (2 of 8) 1 SYMPTOMS ATTRIBUTED TO HEMORRHOIDS • Rectal bleeding - Most common presenting symptom - Bright red blood which may drip or squirt into the toilet bowl or scanty amounts may be seen on toilet tissue • Discomfort due to rectal protrusion or lump • Anal pain • HEMORRHOIDS Anal itching 2 DIAGNOSIS Medical History • Assess nature, duration & severity of symptoms - Ask about bleeding, its amount & frequency - Ask about presence of prolapsing tissue, its timing & reproducibility • Elicit possible risk factors for development of hemorrhoidal symptoms - Low-fi ber diets cause small-caliber stools, resulting in straining during defecation & engorgement of hemorrhoids - Prolonged sitting on a toilet which may cause a problem in the venous return in the perianal area - Pregnancy - Advanced age • Th e signs & symptoms of hemorrhoids are not specifi c to the disease, so care must be taken to avoid missing other causes of pathology • Obtain
    [Show full text]
  • PHARMACEUTICAL Antibiotics and Antibacterial
    PHARMACEUTICAL Antibiotics and Antibacterial Active Ingredient Form Strength Pack Type Packing Style Amoxicillin Sodium Dry Powder Injections 250mg, 500mg, 1000 mg Vial 1's Amoxicillin Suspension 125mg/5ml, 250mg/5ml Bottle 30ml, 60ml Amoxicillin Dispersible Tablet 125mg, 250mg Strip 10's Amoxicillin Trihydrate Tablet 1000mg Blister 10's Amoxicillin + Clavulanate Potassium Injection 500mg + 100mg, 1g + 200mg Vial 10ml, 20ml Amoxicillin + Clavulanate Potassium Suspension 200mg + 28.5mg Bottle 30ml Amoxicillin + clavulanic Acid Tablets 250mg + 125mg, 500mg + 125mg Strip , Alu-Alu 6's, 10's Amoxicillin + Cloxacillin Capsules 250mg + 250mg, 500mg + 500mg Blister 10's Amoxicillin + Cloxacillin Dry Powder Injections 250mg + 250mg Vial 1's Amoxiciilin + Cloxacillin + Lactic Acid Tablet 250 mg + 250 mg + 60 million Tablet 10's Bacillus Spores, 250 + 250 + 120 million Spores Amoxicillin + Flucloxacillin Capsules 250mg + 250mg Strip 10's Azithromycin Tablets 250mg, 500mg Blister 6's, 3's Azithromycin + Fluconazole + Secnidazole Tablet 1gm + 150mg + 1gm Strip 1 + 1 + 2 Betamethasone Valerate + Neomycin Cream 0.1% + 0.5% Tube 10g Sulphate Beclomethasone + Phenylephrine Hcl + Cream 0.025% + 0.10% + 2.5% + 0.1% Tube 10g Lignocaine Hcl + Chlorocresol Betamethasone Valerate Lotion 0.10% Bottle 30ml Betamethasone Injection 4mg/ml Ampoule 1ml Bethamethasone Opthalmic Solution 0.1% w/v Bottle 5ml Betamethasone Valerate Cream 0.1%w/w Tube 15 g Bethamethasone + Gentamicin Cream 0.1% + 0.05% Tube 10 g Betamethasone Sodium Phosphate Tablet 0.5mg Blister 10s
    [Show full text]
  • Download This Issue
    UIP Chapter Meeting - August 25th -27th 2019, Krakow – Poland Contents Foreword 83 UIP Chapter Meeting August 25th -27th 2019, Krakow – Poland 85 Charing Cross International Symposium - Vascular & Endovascular Challenges Update April 15th-18th 2019, London – UK 191 81 Vol 26. No. 3. 2019 Medical Reporters’ Academy The reports from the UIP chapter meeting and Charing cross international symposium were prepared by the following members of the Medical Reporters’ Academy: Roman BREDIKHIN (Russia) Kirill LOBASTOV (Russia) Daniela MASTROIACOVO (Italy) Mustafa SIRLAK (Turkey) Stanislava TZANEVA (Austria) and chaired by: Andrew NICOLAIDES (Cyprus) 82 UIP Chapter Meeting - August 25th -27th 2019, Krakow – Poland Foreword The Medical Reporters’ Academy was co-founded in 1994 as a joint initiative by clinical and research venous disease specialists and Servier; with the main objective to develop an international group of young specialists with a core interest in venous disease drawn from various fields including dermatology, vascular surgery, angiology and/or phlebology. Each year the Medical Reporters’ Academy members are invited by Servier, to cover one of the most important international congresses for venous disease specialists. This year, the UIP Chapter Meeting, which was held in Krakow, Poland on August 25th- 27th, 2019 and the Charing Cross International Symposium: Vascular & Endovascular Challenges Update which was held in London, United Kingdom on April 15th - 18th, 2019 were selected because these congresses involved renowned international and national venous experts and young health care professionals providing a great opportunity to exchange ideas, explore strategies for vein care and discuss the latest trends & innovations in the field. Together with Andrew Nicolaides, the chairman of the group, the academy members explored the program of the congress, selected the events and presentations likely to present breakthroughs or new findings to attend, and wrote short reports.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • Medicines and Related Substances Act No. 101 of 1965
    MEDICINES AND RELATED SUBSTANCES ACT NO. 101 OF 1965 [View Regulation] [ASSENTED TO 19 JUNE, 1965] [DATE OF COMMENCEMENT: 1 APRIL, 1966] (Afrikaans text signed by the State President) This Act was published in Government Gazette 40869 dated 26 May, 2017. as amended by Drugs Control Amendment Act, No. 29 of 1968 Drugs Control Amendment Act, No. 88 of 1970 Drugs Laws Amendment Act, No. 95 of 1971 Drugs Control Amendment Act, No. 65 of 1974 Medicines and Related Substances Control Amendment Act, No. 19 of 1976 Health Laws Amendment Act, No. 36 of 1977 Medicines and Related Substances Control Amendment Act, No. 17 of 1979 Medicines and Related Substances Control Amendment Act, No. 20 of 1981 Transfer of Powers and Duties of the State President Act, No. 97 of 1986 [with effect from 3 October, 1986] Businesses Act, No. 71 of 1991 [with effect from 24 May, 1991] Medicines and Related Substances Control Amendment Act, No. 94 of 1991 General Law Amendment Act, No. 49 of 1996 [with effect from 4 October, 1996] Abolition of Restrictions on the Jurisdiction of Courts Act, No. 88 of 1996 [with effect from 22 November, 1996] Medicines and Related Substances Control Amendment Act, No. 90 of 1997 Medicines and Related Substances Amendment Act, No. 59 of 2002 Judicial Matters Amendment Act, No. 66 of 2008 [with effect from 17 February, 2009] Medicines and Related Substances Amendment Act No. 72 of 2008 Medicines and Related Substances Amendment Act, No. 14 of 2015 GENERAL NOTE There is a discrepancy between the English and Afrikaans texts of section 1 of Act No.
    [Show full text]